NorthWest Biotherapeutics Inc (NWBO)

[antihama]

DD, your point

regarding Iovance Biotherapeutics with FDA-approved lifileucel (to treat adult patients with unresectable or metastatic melanoma) in February 2024. Market cap $ 750 million now thats 80% down since FDA approval

is an interesting one and I was wondering how that would compare to NWBO and DCVax-L. There are a lot of things to look at in making a comparison (MC, SP suppression, regulatory markets, pipeline, etc) but a big biggie in my book that DCVax-L has in its favor that would help maintain its SP is competition within its drug class which translates into revenue. DCVax-L in GBM would have no competition, it would be the go to drug to treat GBM. Lifileucel, on the other hand, in unresectable or metastatic melanoma (and looking at the FDA approval PR, it's a subset of that) has a ton more competition as well as a much smaller # of potential patients (when comparing GBM in United Kingdom vs a subset of metastatic/unresectable melanoma in the US). Looking at the NCCN Guidelines, for 2nd line melanoma, Lifileucel is 1 of 7 preferred treatment options and then there is an additional 11 non-preferred options. That’s a lot of competition in a smaller selective metastatic/ unresectable melanoma market vs DCVax-L in go to first in class glioma. Revenue talks!